National

Canadian farmers to produce less crops due to dry conditions

Aug 30, 2023

Ottawa [Canada], August 30: Canadian farmers are projected to produce less wheat, canola, barley and oats in 2023, according to recent yield model estimates using satellite imagery and agroclimatic data, Statistics Canada said Tuesday.
The decreased production for most crops was driven by lower yields because of dry conditions in western Canada across much of the Prairies, the national statistical agency said.
Wheat production is projected to decrease by 14.2 percent year over year to 29.5 million tonnes in 2023. The yields are expected to fall by 18.6 percent to 41.2 bushels per acre, offsetting higher anticipated harvested area, which is expected to rise 5.6 percent to 26.3 million acres.
Canola production is expected to fall by 6.1 percent to 17.6 million tonnes in 2023. The yields are expected to fall 8.8 percent to 35.4 bushels per acre, while harvested area is expected to increase 3 percent to 21.9 million acres.
Barley production is expected to fall by 20.7 percent to 7.9 million tonnes in 2023 and oat production is to fall by 53.5 percent to 2.4 million tonnes, the lowest production in more than a decade.
Meanwhile, corn for grain production is projected to increase by 1.3 percent to 14.7 million tonnes in 2023 and soybean production is expected to rise by 2.9 percent to 6.7 million tonnes due to higher harvested areas, the agency said.
Statistics Canada has relied on satellite technology and agroclimatic data to model preliminary crop yields and production since 2016.
Source: Xinhua

More news

Concept Medical Announces Successful SIRONA Trial Results, Demonstrating Sirolimus-Coated Balloon as a Promising Alternative for PAD Treatment

Tampa (Florida) [US], January 7: Concept Medical Inc., a global leader in innovative drug-delivery technology, proudly reports positive outcomes from the SIRONA (Head-to-Head Comparison of SIROlimus versus Paclitaxel Drug-Eluting BallooNAngioplasty in the Femoropopliteal Artery) RCT, which show that its sirolimus-coated balloons (SCB) (MagicTouch -PTA) provide patency and functional benefits on par with paclitaxel-coated balloons for patients suffering from peripheral artery disease (PAD). The 1-year data was presented by Principal Investigator Prof. Ulf Teichgraber at the TCT USA 2024 conference in a Late-Breaking Clinical Trials Session (LBCT). Coverage by TCTMD has highlighted these findings, underscoring sirolimus-based therapy as a viable new option in femoropopliteal interventions.

Jan 07, 2025